Merck will stop selling Victrelis in the U.S. by the end of this year. The company cites "advances in treatment practices"--namely, the new all-oral drug cocktails offered by Gilead and AbbVie--and the shrinking demand they've caused.
With its $5.5 billion seller Singulair going off patent in two months, things will be a little dicey for the next couple of years at Merck.
The recommendation by the CDC that the 70 million U.S. baby boomers all be tested for hepatitis C is a big gift for the newest hep C treatments.
Merck ($MRK) has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck...
Merck ($MRK) CEO Kenneth Frazier is deploying his deal team this year with some very specific instructions to step up their game. Speaking to an investor group, the CEO made it clear that the pharma...
It's convenient for hepatitis C market-watchers that Vertex Pharmaceuticals ($VRTX) and Merck ($MRK) reported their earnings less than 24 hours apart. There's no need to speculate about how the two
Merck ($MRK) released its first sales numbers for hepatitis C newbie Victrelis, confirming that rival Vertex Pharmaceuticals ($VRTX) is in the lead. Merck's drug brought in $21 million for the
There's no doubt that the hepatitis C market was waiting for Incivek. In its first five weeks on the market, the Vertex Pharmaceuticals drug reaped nearly $75 million in sales. That's more than twice
The showdown for marketing new oral drugs against hepatitis C is getting hotter. On the heels of gaining EU approval of HCV drug Victrelis (boceprevir), Merck ($MRK) has inked a new deal with Swiss
This could be the drug industry version of Hollywood's first-weekend box office revenues. Vertex Phamaceutical shares spiked on preliminary numbers showing that its new hepatitis C drug is outpacing